"Industrial Layout" stars are shining, "Innovation and Good Medicine" Made in Yantai

The biomedical industry, as a strategic emerging industry with a competitive advantage in Yantai, is responsible for creating an international demonstration city in international life sciences. In 2022, Yantai proposed that biomedicine mainly attacked the development and industrialization of new drugs, and it was called "innovative good medicine and Yantai manufacturing".

Focusing on the key advantageous industry of biomedicine, Yantai first tried the "chain long system" working mechanism, introduced a new round of industrial development support policies, established an industrial development support system, paid close attention to the key points of project breakthroughs, and created a three -dimensional industry with fusion of full -chain elements. Ecology.

A group of hard -approved biomedical companies are becoming a dazzling "star" in the Yantai biomedical industry chain. Among them, there are head companies such as Rongchang, Green Leaf, and Stone Medicine, as well as a number of domestic single championships and unicorn in Zhenghai Biological, Hongyuan Oxygen Industry, and young and new such as Ding Ding Technology and Fengjin. Enterprises can be described as "trees" towering, "shrubs" thrive, and "seedlings" are lush. The development of industrial development has entered a new historical period, showing the gratifying situation of steady industry scale, innovative levels of domestic leadership, and accelerating innovation elements.

In 2022, many projects in Green Leaf Pharmaceuticals were in the listed review stage and phase III clinical/critical test in China and overseas. Among them, the antidepressant new drug LY03005 is the world's first triple re -intake inhibitor (SNDRIS), which has been confirmed from basic research to verification clinical clinical, which are in the listed review stage in China and the United States; In addition to being approved in China, preparations are also in the audit stage of the United States; Palmicate Palibone ketone Smooth Mixed Remarks (LY03010) is in a critical clinical stage in China and the United States for treatment of schizophrenia ...

Breakthroughs in innovation and breakthroughs, thanks to its forward -looking strategic layout in this field, it proves that the design and development, commercial production, clinical trial quality management, and global patent protection of Green Leaf Pharmaceuticals in R & D strategy, innovation systems, process equipment and craft systems Excellent ability and advantage accumulation.

"We adhere to the innovation -driven development strategy. There are R & D centers in China, the United States, and Europe. We have a long -term and targeted preparations national key laboratories and national enterprise technology centers. R & D resources provides unique value products for clinical clinical. "Zhang Xuemei, director of the R & D Center of Green Leaf Pharmaceutical Group's R & D Center, said that Green Leaf Pharmaceutical is based on global R & D, global manufacturing, and global markets. Cardiovascular and other diseases are dedicated to innovating the development and internationalization of drugs.

Talent is the foundation of scientific and technological innovation. Focus on optimizing innovation elements, speed up high -level scientific and technological talents, and continue to strengthen young scientific and technological talents and industrial talent teams. Scientific and technological innovation can have continuous living water and provide high -quality impetus for the development of the pharmaceutical industry.

"We take scientific and technological innovation as the source of power, and take the lead in thinking innovation, management innovation, market innovation, R & D innovation, product innovation and talent innovation, multi -wheel drive, multi -point force, continuous iteration of technology and products, and continuously in the industry segmentation field. Create a new standard and promote the progress of the entire industry. "Walking into the stone medicine exhibition hall, the words on the wall attracted the attention of reporters.

Innovation is endurance, strength, and doing things that others cannot do. Innovation makes the stone medicine people always full of vitality and vitality. "At present, our Biomedical Industrial Park is mainly based on biological and pharmacy -related technical personnel. Among them, most of the employees of more than 60 % of the undergraduate degree, most of the R & D personnel are graduate students with a master's degree or above." Xu Guang, deputy general manager of Shizhen Group, said in the construction of corporate talents.

Jin Youli is the crystallization of the innovative achievements of the stone medicine people. It condenses the original intention of each stone medicine man. In 2011, the Stone Medicine Group Jin Youli was officially launched as the first long -lasting human granulocyte stimulating factor injection, filling the gap of such products in China. In the past 11 years, millions of patients in China have been benefited. "Doing good medicine is to be in China and report to the people of the world", innovation never stops. Xu Guang said that in the future, it will invest in more than 3 billion yuan in the entire 100 -K park and gradually settle in 6-7 new biopots. Taking the existing technical team as the team, gradually expanding the size of the production base. In the future, there are 6-7 workshops being constructed. It is expected that the entire park can reach 100 billion industrial scale after the completion of the park, and industrial employment will reach 2,000 to 3,000 people.

Stone Medicine Group's largest biological industry base, stone medicine, has now become one of the largest anti -tumor drug production bases in Shandong Province. It is also in Muping, focusing on the Qinshui River, and accelerating the construction of multiple pharmaceutical innovation projects. Right now, the Blue Medicine Valley Life Island project is stepping up construction. In the future, it will become the eastern core area of ​​the Yantai biomedical industry. Among them, Shandong Fengjin Biological Engineering Co., Ltd., one of the first batch of start -up projects in Yantai Blue Medicine Valley Super Factory, is developing. The company's total investment is 600 million yuan, and the total planned land area is 130,000 square meters. It has introduced advanced scientific research, production equipment and related process supporting facilities in the industry. Essence

In the layout of Fengjin Group's biomedical large health industry, the three major types of products, including medical beauty products, pharmaceutical grade, medicinal auxiliary materials, food -grade, cosmetic raw materials, and functional skin care products Gold Biological Engineering Co., Ltd. is an important part. "Relying on the background of the pharmaceutical industry, we focus on the development and application of new preparations and new materials. As professional manufacturers of cosmetics, cosmetics raw materials and medical products, we can provide a complete one -stop service of the entire industry chain. Xiao Dongdong, general manager of Shandong Fengjin Biological Engineering Co., Ltd., said, "After the factory (project) is completed, a large number of professional talents will be absorbed and thousands of industrial workers will be employed. Help entrepreneurs to create their own brand and jointly drive the development of beautiful and big health industries together. "" I mainly develop raw materials. "In the laboratory, Zhang Zhaoqian, a post -95 girl who graduated from Shandong University in the laboratory After three invention patents, 3-4 invention patent applications will be submitted this year, and the patent results will be transformed as soon as possible. "Innovation genes have deeply integrated into the corporate culture of Shandong Fengjin Biological Engineering Co., Ltd. The spirit of innovation and practice of employees. In the future, Shandong Fengjin Biological Engineering Co., Ltd. will lead the development of the industry in many biomedical innovation fields such as new materials application, preparation innovation, new product formula, and medical beauty product development, and realize 20 million branches and 200 million cosmetics products annually products and medicine products. Satellite, cosmetics raw material -grade hyaluronic acid, polyaline 50 tons and 20 tons of drug -grade hyaluronic acid.

The biomedical industry has the characteristics of high -tech, high value, and low pollution. It is one of the main directions of my country's strategic emerging industries. It is also an important starting point for promoting the transformation of new and old kinetic energy in the pharmaceutical industry and promoting industrial transformation and upgrading. Innovative drugs are accelerating the layout, and key projects are accelerating, injecting the continuous vitality of injecting the Yantai biomedical industry.

It can be said that the booming development of Yantai biomedicine industry is due to the precise positioning and comprehensive layout of the advantage areas. Under the leadership of the Municipal Party Committee's "1+233" system and "Chain Leveling System", Yantai biomedicine and health industries have been comprehensive, the industrial park system has gradually improved, and the industrial scale has steadily expanded. project. At present, there are 127 companies in Yantai Biomedical Industry Chain, with 55 companies with sales revenue exceeding 100 million yuan, 13 companies with more than one billion yuan, 3 national specialty new giant companies, 9 gazelle companies, and provincial manufacturing industry There are 4 single championships and 11 special "major new drug creation" in the country.

Yantai biomedicine is well -known, and forged the highlights of the international event of the biomedical industry. At the international conference just held in 2022 pharmaceutical innovation and development, Yantai promoted the pharmaceutical industry policies worldwide, issued an invitation of "industrial chain partners", and invited international and domestic industry leading enterprises, innovation and entrepreneurial enterprises, head investment enterprises, high -level scientific research research Institution, innovative talent (team). The conference also pointed out that in order to further explore the new ideas and new paths of the development of the biopharmaceutical industry in the new era, Yantai vigorously implemented major projects, biomedical industry chain breakthrough projects, and strategic emerging industry intensive development projects. Create an innovative ecosystem, promote the deep integration of the industrial chain, innovation chain, and supply chain, and promote the transformation and upgrading of the biomedical industry.

The excellent market environment, strong basic heritage, precise industrial positioning and comprehensive strategic layout are litting the "innovation engine" manufactured by Yantai. In the next step, Yantai will rely on the "chain length system" to boldly innovate the practice, calling the "innovative medicine, Yantai manufacturing" brand, and build a "international life science demonstration city" to inject new kinetic energy into the innovation and development of the world's biomedical industry. Continue to write a new grand chapter for the high -quality development of Yantai in the new era.

- END -